Nigerian Journal Sustainability Research

FDA Recall Alert: Thyroid Tablets Pulled Nationwide Over "Superpotency" Risk

2026-08-25
The Affected Product

Vitruvias Therapeutics, Inc., based in Auburn, Alabama, announced a voluntary nationwide recall on August 21, 2026, of one specific lot of Thyroid Tablets, USP 30 mg. The recall covers Lot No. 504950 at the consumer level. If you or someone you care for takes this medication, the first step is to check the bottle for that exact lot number rather than assuming the whole drug or dosage is affected, this is a single-lot recall, not a broad recall of all Thyroid Tablets USP 30 mg on the market.

Why It Was Recalled

The recall was triggered because testing confirmed the tablets in this lot have the potential to be superpotent, meaning they may contain more active thyroid hormone than intended. That's a meaningfully different problem from a typical recall involving contamination or subpotency (too little active ingredient); here, the concern runs in the opposite direction.

The Health Risk

Superpotent thyroid tablets can push a patient into hyperthyroidism (an overactive thyroid), and the FDA's recall notice lists a fairly extensive set of possible symptoms:

  • Unexplained weight loss
  • Heat intolerance
  • Fatigue
  • Nervousness
  • Muscle weakness
  • Hypertension
  • Chest pain
  • Rapid heart rate or heart rhythm disturbances

The FDA specifically flagged that elderly patients, pregnant women, and infants face elevated risk of adverse effects from this issue, particularly with extended exposure over time.

What to Do If You Have This Medication

Do not stop taking the medication on your own. The FDA and Vitruvias Therapeutics are both explicit on this point: patients currently taking the affected product should contact their healthcare provider before discontinuing use, since abruptly stopping thyroid medication carries its own risks. Your doctor can help arrange a replacement prescription if your bottle matches the recalled lot.

As of the recall announcement, Vitruvias Therapeutics said it had not received any reports of adverse events connected to this lot. Consumers with questions can contact Vitruvias Therapeutics directly for further guidance.

A Separate, Earlier Recall Worth Knowing About Too

It's worth flagging that this isn't the only thyroid medication recall active this year, since headlines and search results can blur together. A separate recall was issued in July 2026 for levothyroxine sodium tablets manufactured by Major Pharmaceuticals and distributed by Cardinal Health. That recall, initiated July 13, 2026, was for a different reason entirely: those tablets were found to be subpotent (containing less active ingredient than labeled) rather than superpotent, meaning patients could unknowingly receive too little thyroid hormone and see hypothyroidism symptoms return. That recall covered dosage strengths of 25, 50, 75, 88, 112, and 150 micrograms, with expiration dates ranging from July 2026 to January 2027, packaged in 100-tablet cartons of ten 10-tablet blister packs.

These are two distinct recalls, from two different manufacturers, for opposite potency problems, so if you take a thyroid medication, it's worth checking both your drug name (Thyroid Tablets USP vs. levothyroxine sodium) and lot number against the specific recall that applies to you.

Bottom Line

Given that generic levothyroxine and thyroid tablets are manufactured and distributed by many different companies, having a matching dosage strength does not automatically mean your specific bottle is affected. The safest move is to check your bottle's manufacturer name and lot number directly, or ask your pharmacist to verify it against their purchasing and dispensing records, and to contact your healthcare provider with any questions before making changes to your medication routine.

Sources